Selection statistics published by Specifica put roughly 60 percent of antibodies taken directly from its Generation 3 libraries at affinities below 10 nM, 20 percent in the subnanomolar range, and its best clone to date at 13 pM, with more than 80 percent showing no measurable biophysical liabilities. After selection, the machine learning module of AbXtract sorts hits into as many as 1,000 distinct clusters, giving coverage across a wide range of target epitopes. Libraries are supplied as exclusive assets: each HCDR3 donor is used only once and the remaining CDRs are reassembled for each library, so the diversity belongs to one partner alone. Customers can take a full platform transfer, arriving with libraries, vectors, protocols and training, commission custom builds that alter scaffolds, tags, vectors or excluded liabilities, or hand campaigns to the Santa Fe team instead. VHH single domain formats, reagents, R&D services and tiered antibody data packages for training AI and machine learning models complete the offering. The laboratories sit in the Railyard district of Santa Fe, New Mexico.
Specifica
Specifica, a Q2 Solutions company, is a prominent antibody discovery provider utilizing its proprietary Generation 3 antibody libraries and advanced next-generation sequencing (NGS) analysis platforms. Delivering highly diverse, developable, and natural human antibody leads with exceptional biophysical profiles, Specifica empowers biopharmaceutical partners to bypass traditional optimization bottlenecks.
